Search Results for “EC” – Page 233 – media

Study shows cholesterol-lowering drug reduces diabetic retinopathy risk

A study conducted by Oxford Population Health has demonstrated that a cholesterol-lowering drug could help reduce the risk of eye disease in people living with diabetes. The Lowering Events in Non-proliferative retinopathy in Scotland (LENS) trial has been investigating the effect of fenofibrate on retinopathy in patients living with diabetes and early retinopathy. Estimated to affect around 415 million people worldwide, diabetes is a chronic, metabolic disease that is characterised by elevated levels of blood glucose, which can lead to serious damage to the heart, blood vessels, eyes, kidneys and nerves. Globally, the prevalence of diabetic retinopathy among diabetic patients is estimated to be 27%. As part of the national routine diabetic eye screening programme, the LENS trial compared the effects of fenofibrate with a placebo in 1,151 adults with type 1 or type 2 diabetes in Scotland who had early-to-moderate diabetic retinopathy. Sold under several brand names, including Tricor ...
- Source: drugdu
- 85
- June 29, 2024
Customizable AI Tool Helps Pathologists Identify Diseased Cells

Pathologists are tasked with examining body fluids or tissues to diagnose diseases, a process that involves distinguishing rare disease-indicating cells from thousands of normal cells under a microscope. This skill requires extensive training. Artificial intelligence (AI) can assist by learning to differentiate between healthy and diseased cells from digital pathology images. However, traditional AI tools, once trained, lack flexibility. They are designed for specific tasks, such as identifying cancer cells in one organ but not another, and might not align perfectly with a pathologist’s specific needs in different scenarios. Now, a collaborative team of computer scientists and physicians has developed a new AI tool that not only identifies diseased cells but also adapts to a pathologist’s requirements. Developed at Stanford Medicine (Stanford, CA, USA), the tool, named nuclei.io, functions like a human assistant that evolves with feedback. Starting with the basic function of recognizing different cell types by their nuclei, ...
- Source: drugdu
- 93
- June 28, 2024
Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease

The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications. By Frank VinluanA Novo Nordisk drug for hypertension and chronic kidney disease has failed a pivotal study, a setback to the Danish pharmaceutical giant’s effort to bring patients a new therapy with potential safety and efficacy advantages over currently approved medications in the drug class, including a product marketed by Bayer. Novo Nordisk did not release specific details about the Phase 3 results for the drug, ocedurenone. The company said Wednesday that an independent data monitoring committee recommended stopping the trial after a prespecified interim analysis. Ocedurenone is a small molecule designed to block the mineralocorticoid receptor. When overactivated, this receptor can contribute to ...
- Source: drugdu
- 97
- June 28, 2024
Lilly joins fellow pharma giants in OpenAI partnership

Eli Lilly has joined a growing list of pharma companies to partner with OpenAI, as it seeks to develop new treatments for drug-resistant pathogens. The collaboration will utilise the generative artificial intelligence (genAI) from OpenAI to come up with new solutions for microbial infections. Lilly didn’t specify the exact details of how OpenAI’s technology will be used, or any financial terms of the deal. Lilly joins Sanofi and Moderna, who have both unveiled partnerships with the genAI platform OpenAI this year. Last month, Sanofi announced that it was partnering with Formation Bio and OpenAI to harness AI to expedite drug development. On the other hand, Moderna has incorporated ChatGPT into an internal messaging platform called mChat, to harness data analytics, and use image generation, and dose selection. This new collaboration with OpenAI builds on Lilly’s commitment to tackle antimicrobial resistance (AMR). The pharma giant previously contributed $100m to the AMR ...
- Source: drugdu
- 104
- June 28, 2024
Health Asia

Organiser：Ecommerce Gateway Pakistan (Pvt.) Ltd Time：October 17-19, 2024 Address：Karachi Expo Center, University Rd, Gulshan-e-Iqbal, Karachi, Pakistan Exhibition hall：Karachi Expo Center Product range: Medical Supplies: Medical diagnostic equipment, pharmaceuticals, electronic medical equipment and instruments, rescue equipment, medical reagent equipment, disposable medical equipment. Hospital Supplies: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical medical instruments, medical clothing and bedding, hospital furniture, emergency equipment, maternal and child care equipment, sterilization equipment, orthopedic prostheses, air filtration devices, blood pressure diagnostic instruments, heart rate monitors, ultrasound equipment, X-ray diagnostic equipment, urology and transplantation services, dialysis machines, physical therapy equipment. Laboratory Equipment: Laboratory instruments and equipment, optical instruments and equipment, image analysis and processing systems, testing instruments and devices, quality inspection equipment, laboratory renovation and upgrading technology, consumables, and related software. Pharmaceutical and Healthcare: Ophthalmology drugs, orthopedic drugs, traditional Chinese medicine, western medicine, traditional Chinese medicine health care drugs, nutritious foods, pharmaceutical intermediates, ...
- Source: drugdu
- 150
- June 28, 2024
【EXPERT Q&A】Is it easy to apply for the EU CE certification?

Drugdu.com expert’s response: CE certification is a certification system established by the European Union to ensure the safety of products for people, animals, and objects. For companies that want to export their products to EU member states, CE certification is essential. From a process perspective, CE certification is not complicated, mainly including filling out an application form, providing product information, sending samples for testing, and obtaining a certificate or report after passing the test. The entire process is usually completed within 5-7 working days. Therefore, from an operational level, CE certification is relatively easy to apply for. However, it should be noted that the preparation of technical documents involved in CE certification is relatively cumbersome, including but not limited to the product name, model, instruction manual, safety design documents, technical conditions, electrical schematics, etc. Enterprises need to ensure that these documents are complete, accurate, and comply with relevant EU standards.
- Source: drugdu
- 89
- June 28, 2024
Customizable AI Tool Helps Pathologists Identify Diseased Cells

Pathologists are tasked with examining body fluids or tissues to diagnose diseases, a process that involves distinguishing rare disease-indicating cells from thousands of normal cells under a microscope. This skill requires extensive training. Artificial intelligence (AI) can assist by learning to differentiate between healthy and diseased cells from digital pathology images. However, traditional AI tools, once trained, lack flexibility. They are designed for specific tasks, such as identifying cancer cells in one organ but not another, and might not align perfectly with a pathologist’s specific needs in different scenarios. Now, a collaborative team of computer scientists and physicians has developed a new AI tool that not only identifies diseased cells but also adapts to a pathologist’s requirements. Developed at Stanford Medicine (Stanford, CA, USA), the tool, named nuclei.io, functions like a human assistant that evolves with feedback. Starting with the basic function of recognizing different cell types by their nuclei, ...
- Source: drugdu
- 143
- June 27, 2024
Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease

The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications. By Frank Vinluan A Novo Nordisk drug for hypertension and chronic kidney disease has failed a pivotal study, a setback to the Danish pharmaceutical giant’s effort to bring patients a new therapy with potential safety and efficacy advantages over currently approved medications in the drug class, including a product marketed by Bayer. Novo Nordisk did not release specific details about the Phase 3 results for the drug, ocedurenone. The company said Wednesday that an independent data monitoring committee recommended stopping the trial after a prespecified interim analysis. Ocedurenone is a small molecule designed to block the mineralocorticoid receptor. When overactivated, this receptor can contribute to ...
- Source: drugdu
- 102
- June 27, 2024
Chiatai Tianqing’s Liraglutide Approved for Listing, Formally Entering the Field of Biological Drugs to Control Glucose

On June 25, Chiatai Tianqing received the Certificate of Drug Registration approved by the State Drug Administration, and the company’s liraglutide injection was approved to be listed in the market, which is used for controlling blood glucose in adult patients with type 2 diabetes mellitus. This is the ninth new product (including new indications) approved by Chiatai Tianqing since this year. The approval of this product also marks Chiatai Tianqing’s formal entry into the field of biopharmaceutical glycemic control. Liraglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1) with 97% homology to natural GLP-1, an endogenous enteric insulinotropic hormone that enhances glucose-dependent insulin secretion from pancreatic β-cells. In addition to pancreatic islet cells, GLP-1 receptors are widely present in gastrointestinal, lung, brain, kidney, cardiovascular system and other organs and tissues. Liraglutide prolongs the half-life of GLP-1 on the basis of retaining the physiological action characteristics of GLP-1, and needs to ...
- Source: drugdu
- 86
- June 27, 2024
Europe contributes over €750m to African Vaccines Manufacturing Accelerator

The EU, its Member States and European financial institutions have announced a more than €750m contribution to the newly launched African Vaccines Manufacturing Accelerator (AVMA) as part of the EU’s Global Gateway strategy. Over the next decade, the AVMA aims to purchase more than 800 million vaccine doses produced in Africa, making more than €1bn available to manufacturers to offset high start-up costs while providing assurance of demand. Developed by Gavi, the Vaccine Alliance and the Africa Centres for Disease Control and Prevention, the AVMA has the potential to improve African pandemics, outbreaks, preparedness and responses, as well as to support global health security. It aims to enhance the predictability of demand for vaccines made in Africa, support the growth of its manufacturing base and achieve its ambition to produce most vaccines required by African countries on the continent while also helping to diversify a set of global vaccine suppliers ...
- Source: drugdu
- 84
- June 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.